MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 179 filers reported holding MIRATI THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.52 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,387,524 | +73.6% | 54,810 | +44.0% | 0.00% | +50.0% |
| Q2 2023 | $1,375,614 | -43.6% | 38,074 | -42.0% | 0.00% | -33.3% |
| Q1 2023 | $2,440,309 | -84.7% | 65,635 | -81.3% | 0.00% | -87.5% |
| Q4 2022 | $15,928,595 | -99.6% | 351,547 | +462.2% | 0.02% | +242.9% |
| Q3 2022 | $4,366,956,000 | +1265.2% | 62,528 | +1212.2% | 0.01% | – |
| Q2 2022 | $319,874,000 | -85.7% | 4,765 | -82.4% | 0.00% | -100.0% |
| Q1 2022 | $2,232,026,000 | -63.1% | 27,147 | -34.2% | 0.00% | -66.7% |
| Q4 2021 | $6,050,669,000 | +2879.3% | 41,248 | +3493.0% | 0.01% | – |
| Q3 2021 | $203,093,000 | +93.1% | 1,148 | +76.3% | 0.00% | – |
| Q2 2021 | $105,156,000 | -88.9% | 651 | -88.3% | 0.00% | -100.0% |
| Q1 2021 | $950,201,000 | -41.4% | 5,547 | -24.9% | 0.00% | -66.7% |
| Q4 2020 | $1,621,822,000 | +11.4% | 7,384 | -15.8% | 0.00% | +50.0% |
| Q3 2020 | $1,456,425,000 | +235.3% | 8,771 | +130.5% | 0.00% | +100.0% |
| Q2 2020 | $434,417,000 | -64.8% | 3,805 | -76.3% | 0.00% | -66.7% |
| Q1 2020 | $1,235,685,000 | +136.1% | 16,075 | +295.8% | 0.00% | +200.0% |
| Q4 2019 | $523,300,000 | +36.4% | 4,061 | -17.5% | 0.00% | 0.0% |
| Q3 2019 | $383,629,000 | +18.2% | 4,924 | +56.2% | 0.00% | 0.0% |
| Q2 2019 | $324,656,000 | -8.3% | 3,152 | -34.8% | 0.00% | 0.0% |
| Q1 2019 | $354,186,000 | +1170.3% | 4,832 | +716.2% | 0.00% | – |
| Q3 2018 | $27,883,000 | -4.5% | 592 | 0.0% | 0.00% | – |
| Q2 2018 | $29,186,000 | +126795.7% | 592 | +29500.0% | 0.00% | – |
| Q3 2017 | $23,000 | +228.6% | 2 | 0.0% | 0.00% | – |
| Q2 2017 | $7,000 | -99.7% | 2 | -99.6% | 0.00% | – |
| Q1 2017 | $2,434,000 | -32.4% | 468 | -38.3% | 0.00% | – |
| Q4 2016 | $3,601,000 | -39.5% | 758 | -15.9% | 0.00% | – |
| Q3 2016 | $5,956,000 | +102.0% | 901 | +66.9% | 0.00% | – |
| Q2 2016 | $2,948,000 | -95.9% | 540 | -76.2% | 0.00% | – |
| Q4 2015 | $71,668,000 | +0.4% | 2,268 | +9.4% | 0.00% | – |
| Q3 2015 | $71,387,000 | +173.6% | 2,074 | +150.2% | 0.00% | – |
| Q2 2015 | $26,089,000 | +349.4% | 829 | +318.7% | 0.00% | – |
| Q1 2015 | $5,805,000 | +176.3% | 198 | +65.0% | 0.00% | – |
| Q3 2014 | $2,101,000 | – | 120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $688,784,000 | 67.42% |
| Avoro Capital Advisors LLC | 4,535,000 | $996,067,000 | 17.15% |
| Darwin Global Management, Ltd. | 260,876 | $57,299,000 | 15.99% |
| Boxer Capital, LLC | 1,765,560 | $387,788,000 | 12.46% |
| Perceptive Advisors | 3,693,516 | $811,244,000 | 8.71% |
| Consonance Capital Management LP | 330,000 | $72,481,000 | 6.77% |
| EcoR1 Capital, LLC | 464,298 | $101,978,000 | 5.48% |
| Fairmount Funds Management LLC | 60,500 | $13,288,000 | 4.75% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,400 | $14,804,000 | 4.04% |
| RTW INVESTMENTS, LP | 1,054,364 | $231,581,000 | 3.88% |